PCSA (Processa Pharmaceuticals) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals Days Payable?

Processa Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2024 was $0.83 Mil. Processa Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Processa Pharmaceuticals's Days Payable or its related term are showing as below:

During the past 13 years, Processa Pharmaceuticals's highest Days Payable was 629.22. The lowest was 456.98. And the median was 543.10.

PCSA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.14
* Ranked among companies with meaningful Days Payable only.

Processa Pharmaceuticals's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Processa Pharmaceuticals Days Payable Historical Data

The historical data trend for Processa Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Processa Pharmaceuticals Days Payable Chart

Processa Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Processa Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Processa Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Processa Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Days Payable falls into.

Processa Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Processa Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.328	+	0.312)	/	2 )	/	0	*	365
=	0.32					/	0	*	365
=	N/A

Processa Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (0.953	+	0.712)	/	2 )	/	0	*	365 / 4
=	0.8325					/	0	*	365 / 4
=	N/A

Processa Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Processa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076

Website

https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Executives

David Young	director, 10 percent owner, officer: President & CEO	8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Patrick Lin	officer: Chief Business - Strategy Off	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
George K Ng	officer: Chief Executive Officer	C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Justin W Yorke	director	C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
Wendy Guy	officer: Chief Administrative Officer	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker	officer: Chief Financial Officer	9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal	director	2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson	director	319 SOUTH NARDO, SOIANA BEACH CA 92075
Geraldine Pannu	director	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Robert Michael Floyd	officer: Chief Operating Officer	C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora	officer: Chief Development Officer	7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076